Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 11

1.

Dose reduction effective in alleviating symptoms of saquinavir toxicity.

Stephan C, Carlebach A, Rottmann C, Haberl A, Dauer B, von Hentig N, Kurowski M, Staszewski S.

Int J STD AIDS. 2007 Feb;18(2):81-4.

PMID:
17331276
2.

Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen.

von Hentig N, Müller A, Rottmann C, Wolf T, Lutz T, Klauke S, Kurowski M, Oertel B, Dauer B, Harder S, Staszewski S.

Antimicrob Agents Chemother. 2007 Apr;51(4):1431-9. Epub 2007 Feb 12.

3.

Pharmacokinetics and tolerability of a combination of indinavir, lopinavir and ritonavir in multiply pretreated HIV-1 infected adults.

von Hentig N, Müller A, Rottmann C, Lutz T, Klauke S, Kurowski M, Staszewski S, Harder S.

Eur J Med Res. 2006 Jun 30;11(6):236-44.

PMID:
16820336
4.

Mega-HAART: preliminary results and correlation with baseline resistance.

Rottmann C, Miller V, Staszewski S.

Antivir Ther. 1999;4 Suppl 3:93-4.

PMID:
16021879
5.

Severe CNS side-effect and persistent high efavirenz plasma levels in a patient with HIV/HCV coinfection and liver cirrhosis.

Bickel M, Stephan C, Rottmann C, Carlebach A, Haberl A, Kurowski M, Staszewski S.

Scand J Infect Dis. 2005;37(6-7):520-2.

PMID:
16012018
6.

The Protease Inhibitor Transfer Study (PROTRA 1): abacavir and efavirenz in combination as a substitute for a protease inhibitor in heavily pretreated HIV-1-infected patients with undetectable plasma viral load.

Bickel M, Rickerts V, Stephan C, Jacobi V, Rottmann C, Dauer B, Carlebach A, Thalhammer A, Miller V, Staszweski S.

HIV Med. 2005 May;6(3):179-84.

7.

[Clinical presentation and management of the severe acute respiratory syndrome (SARS)].

Rickerts V, Wolf T, Rottmann C, Preiser W, Drosten C, Jakobi V, Leong HN, Brodt HR.

Dtsch Med Wochenschr. 2003 May 16;128(20):1109-14. German.

PMID:
12748900
8.

A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.

Staszewski S, Haberl A, Carlebach A, Rottmann C, Miller V, Gute P.

HIV Med. 2000 Jul;1(3):162-3. No abstract available.

9.

The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.

Miller V, Sabin CA, Phillips AN, Rottmann C, Rabenau H, Weidmann E, Rickerts V, Findhammer S, Helm EB, Staszewski S.

AIDS. 2000 Sep 29;14(14):2129-36.

PMID:
11061654
10.

CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.

Miller V, Staszewski S, Sabin C, Carlebach A, Rottmann C, Weidmann E, Rabenau H, Hill A, Lepri AC, Phillips AN.

J Infect Dis. 1999 Aug;180(2):530-3.

11.

Dual resistance to zidovudine and lamivudine in patients treated with zidovudine-lamivudine combination therapy: association with therapy failure.

Miller V, Phillips A, Rottmann C, Staszewski S, Pauwels R, Hertogs K, de Béthune MP, Kemp SD, Bloor S, Harrigan PR, Larder BA.

J Infect Dis. 1998 Jun;177(6):1521-32.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk